# Chromium Fasting Glucose Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/chromium-fasting-glucose-meta-analysis-evidence-review
Category: evidence-review
Summary: Chromium Fasting Glucose Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are 
Last reviewed: 2026-07-05
Reviewed by: Migaku Evidence Review
# Chromium Fasting Glucose Meta-analysis: What the Evidence Says

## Quick Answer

Chromium Fasting Glucose Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes | systematic review | 1 | 2026-05-15 | 10.2147/DMSO.S581925 |
| Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention | preclinical study | 4 | 2026-03-08 | 10.3390/nu18050868 |

## What The Sources Report

- Table 1 Aspect Details References Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and diabetes. [Babakr Abdullatif Taha (2026); evidence level 1]
- Common risk factors include obesity (BMI ≥ 25 kg/m), increased waist circumference (>102 cm for men, >88 cm for women), hypertension, smoking, hyperlipidemia, age > 40 years, and a history of gestational diabetes. [Babakr Abdullatif Taha (2026); evidence level 1]
- Dysglycemia represents a heterogeneous clinical condition located along a pathophysiological continuum between normoglycemia and type 2 diabetes mellitus (T2DM) and is associated with a progressive and measurable increase in cardiometabolic risk, already evident in the early stages. [Cicero Arrigo Francesco Giuseppe (2026); evidence level 4]
- Evidence derived from cohort studies and meta-analyses indicates that so-called prediabetes is not a metabolically neutral condition but rather an early disease stage characterized by increased all-cause and cardiovascular mortality. [Cicero Arrigo Francesco Giuseppe (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For chromium fasting glucose meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Babakr Abdullatif Taha (2026). Chromium as a Modulator of Insulin Receptor Activity: A Systematic Review of Its Role in Metabolic Syndrome and Type 2 Diabetes. DOI: 10.2147/DMSO.S581925. PMCID: PMC13186220. PMID: 42163851. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13186220/
- Cicero Arrigo Francesco Giuseppe (2026). Dysglycemia and Cardiometabolic Risk: Pathophysiological Rationale and the Emerging Role of Nutraceuticals in Integrated Prevention. DOI: 10.3390/nu18050868. PMCID: PMC12986585. PMID: 41830038. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12986585/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.